Literature DB >> 18795925

Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.

R Foster1, E Byrnes, C Meldrum, R Griffith, G Ross, E Upjohn, A Braue, R Scott, G Varigos, P Ferrao, L K Ashman.   

Abstract

BACKGROUND: The receptor tyrosine kinase c-KIT plays a key role in normal mast cell development. Point mutations in c-KIT have been associated with sporadic or familial mastocytosis.
OBJECTIVES: Two unrelated pairs of apparently identical twins affected by cutaneous mastocytosis attending the Mastocytosis Clinic at the Royal Children's Hospital, Melbourne, provided an opportunity to assess the possible contribution of c-KIT germline mutations or polymorphisms in this disease.
METHODS: Tissue biopsy, blood and/or buccal swab specimens were collected from 10 children with mastocytosis. To detect germline mutations/polymorphisms in c-KIT, we studied all coding exons by denaturing high pressure liquid chromatography. Exons showing mismatches were examined by direct sequencing. The influence of the substitution identified was further examined by expressing the variant form of c-KIT in factor-dependent FDC-P1 cells.
RESULTS: In both pairs of twins, a heterozygous ATG to CTG transition in codon 541 was observed, resulting in the substitution of a methionine residue in the transmembrane domain by leucine (M541L). In each case, one parent was also heterozygous for this allele. Expression of M541L KIT in FDC-P1 cells enabled them to grow in human KIT ligand (stem cell factor, SCF) but did not confer factor independence. Compared with cells expressing wild-type KIT at a similar level, M541L KIT-expressing cells displayed enhanced growth at low levels of SCF, and heightened sensitivity to the KIT inhibitor, imatinib mesylate.
CONCLUSIONS: The data suggest that the single nucleotide polymorphism resulting in the substitution M541L may predispose to paediatric mastocytosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795925     DOI: 10.1111/j.1365-2133.2008.08827.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

1.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

Review 2.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

3.  Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.

Authors:  Yarden Opatowsky; Irit Lax; Francisco Tomé; Franziska Bleichert; Vinzenz M Unger; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

4.  Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.

Authors:  Gerhard J Molderings; Kirsten Meis; Ulrich W Kolck; Jürgen Homann; Thomas Frieling
Journal:  Immunogenetics       Date:  2010-09-14       Impact factor: 2.846

5.  The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.

Authors:  Niyaz Zaman; Serena Santhana Dass; Persephone DU Parcq; Suzanne Macmahon; Lewis Gallagher; Lisa Thompson; Jamshid S Khorashad; Clara LimbÄck-Stanic
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

6.  Prevalence and significance of M541L single nucleotide polymorphism in the central European cohort of gastrointestinal stromal tumor patients.

Authors:  Karin Jasek; Marian Grendar; Andrea Stanclova; Bibiana Malicherova; Ivana Kasubova; Tatiana Burjanivova; Peter Szepe; Rachele Ciccocioppo; Luis Rodrigo; Robert Prosecky; Peter Kruzliak; Lukas Plank; Zora Lasabova
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-12       Impact factor: 4.553

7.  Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.

Authors:  Z Li; F Stölzel; K Onel; M Sukhanova; M K Mirza; K L Yap; O Borinets; R A Larson; W Stock; M M Sasaki; L Joseph; G Raca
Journal:  Leukemia       Date:  2015-03-19       Impact factor: 11.528

8.  Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.

Authors:  Jian-Wei Zhang; Tao Qin; Shao-Dong Hong; Jing Zhang; Wen-Feng Fang; Yuan-Yuan Zhao; Yun-Peng Yang; Cong Xue; Yan Huang; Hong-Yuan Zhao; Yu-Xiang Ma; Zhi-Huang Hu; Pei-Yu Huang; Li Zhang
Journal:  Chin J Cancer       Date:  2015-04-08

Review 9.  Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.

Authors:  Ruchi Pandey; Reuben Kapur
Journal:  Mol Cancer       Date:  2015-06-11       Impact factor: 27.401

10.  KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.

Authors:  Mehdi Brahmi; Laurent Alberti; Armelle Dufresne; Isabelle Ray-Coquard; Philippe Cassier; Pierre Meeus; Anne-Valérie Decouvelaere; Dominique Ranchère-Vince; Jean-Yves Blay
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.